AI drug development’s data problem
Science · 11.04.2025 · 388 (6743) · 131-131
DOI: 10.1126/science.adx0339 ↗Kurz gefasst
Editorial in der Zeitschrift Science, erschienen am 11.04.2025. Verfasst von E Richard Gold und 1 weiteren Autor:innen. Beteiligte Einrichtung: E. Richard Gold is at the Faculty of Law and Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada; is Chief Policy and Pa…. Hauptthemen laut MEDLINE: Artificial Intelligence, Drug Development, Drug Discovery. Die Arbeit wurde bisher 16-mal zitiert (Crossref).
Abstract (Originalsprache)
The future of drug discovery may be artificial intelligence (AI), but its present is not. AI is in its infancy in the field. To help AI mature, developers need nonproprietary, open, large, high-quality datasets to train and validate models, managed by independent organizations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- E. Richard Gold is at the Faculty of Law and Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada; is Chief Policy and Partnerships Officer, Conscience, Toronto, ON, Canada; and is senior fel…
- Robert Cook-Deegan is at the School for the Future of Innovation in Society and Consortium for Science, Policy and Outcomes, Arizona State University, Washington, DC, USA.
Zitieren
APA
Gold, E. R., & Cook-Deegan, R. (2025). AI drug development’s data problem. Science, 388(6743), 131-131. https://doi.org/10.1126/science.adx0339
Vancouver
Gold ER, Cook-Deegan R. AI drug development’s data problem. Science. 2025;388(6743):131-131. doi:10.1126/science.adx0339
BibTeX
@article{Gold2025,
author = {Gold, E Richard and Cook-Deegan, Robert},
title = {AI drug development’s data problem},
journal = {Science},
year = {2025},
volume = {388},
number = {6743},
pages = {131--131},
doi = {10.1126/science.adx0339}
}
EUVIMED